Mon. 1 Apr 2024, 10:05am ET
Benzinga
Earnings, Earnings Beats, News
CARISMA Therapeutics (NASDAQ:CARM) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.55) by 5.45 percent. The company reported quarterly sales of $4.29 million which beat the analyst consensus estimate of $2.90 million by 47.90 percent.